Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity

This study has been completed.

Sponsor:

Information provided by:

Gachon University Gil Medical Center

ClinicalTrials.gov Identifier:

NCT00546182

First received: October 17, 2007

Last updated: NA

Last verified: October 2007

History: No changes posted

Tracking Information

First Received Date ^ICMJE

October 17, 2007

Last Updated Date

October 17, 2007

Start Date ^ICMJE

January 2004

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity

Official Title ^ICMJE

Phase 4 Study of Simvastatin That Affects Insulin Sensitivity

Brief Summary

We hypothesized simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients.

Detailed Description

Not Provided

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Observational Model: Case Control
Time Perspective: Prospective

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Not Provided

Study Population

overweight hypercholesterolemic patients

Condition ^ICMJE

Hypercholesterolemia

Intervention ^ICMJE

Not Provided

Study Group/Cohort (s)

Not Provided

Publications *

Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999 Mar;126(5):1205-13.

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Not Provided

Completion Date

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Low-density lipoprotein cholesterol levels more than 100 and body mass index more than 23.0

Exclusion Criteria:

Patients with overt liver disease
Chronic renal failure
Hypothyroidism, myopathy
Uncontrolled diabetes
Severe hypertension, stroke
Acute coronary events
Coronary revascularization within the preceding 3 months, or
Alcohol abuse.

Gender

Both

Ages

25 Years to 75 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Korea, Republic of

Administrative Information

NCT Number ^ICMJE

NCT00546182

Other Study ID Numbers ^ICMJE

GMC-200405

Has Data Monitoring Committee

Yes

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Gachon University Gil Medical Center

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Kwang K Koh, MD,PhD

Gachon University Gil Medical Center

Information Provided By

Gachon University Gil Medical Center

Verification Date

October 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top